September 2, 2002
AstraZeneca: Iressa for NSCLC AstraZeneca launched its drug for non-small cell lung cancer Iressa (gefitinib) on August 30 following the approval of its NHI price listing at \7,216.10 per tablet by Chuikyo on August 21. Gefitinib is a molecular target-based...read more